Protease-Activated Receptor 1 (PAR1) Expression Contributes to HPV-Associated Oropharyngeal Cancer Prognosis.
Female
Humans
Biomarkers, Tumor
/ analysis
Carcinoma, Squamous Cell
/ pathology
Cyclin-Dependent Kinase Inhibitor p16
/ analysis
Human Papillomavirus Viruses
Oropharyngeal Neoplasms
/ pathology
Papillomavirus Infections
/ diagnosis
Prognosis
Receptor, PAR-1
/ genetics
Tumor Microenvironment
Uterine Cervical Neoplasms
Arrestin domain-containing 3
Oropharyngeal cancer
Protease-activated receptor 1
Tumor-infiltrating lymphocyte
Journal
Head and neck pathology
ISSN: 1936-0568
Titre abrégé: Head Neck Pathol
Pays: United States
ID NLM: 101304010
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
22
05
2023
accepted:
17
06
2023
pmc-release:
24
07
2024
medline:
22
9
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
ppublish
Résumé
Human papillomavirus (HPV)-associated oropharyngeal cancer occasionally has a poor prognosis, making prognostic risk stratification crucial. Protease-activated receptor-1 (PAR1) is involved in carcinogenesis, and its expression is regulated by alpha-arrestin domain-containing protein 3 (ARRDC3). It is also involved in the tumor microenvironment. We sought to evaluate the predictive ability of PAR1, ARRDC3, and tumor-infiltrating lymphocyte (TIL) scores in patients with oropharyngeal, hypopharyngeal, and uterine cervical cancers, serving as comparators for HPV-associated oropharyngeal cancer. Immunohistochemical analysis of p16, ARRDC3, and PAR1 expression was performed on 79 oropharyngeal, 44 hypopharyngeal, and 42 uterine cervical cancer samples. The TIL scores were assessed and classified into the following groups based on invasion: low: 0-10%, medium: 20-40%, and high: > 50%. For prognostic analysis, the three groups were evaluated by dividing them into low, medium, and high categories, or alternatively into two groups using the median value as the cutoff. p16 was expressed in 44 (56%) oropharyngeal, 8 (18%) hypopharyngeal, and all uterine cervical cancer samples. ARRDC3 was detected in 39 (49%) oropharyngeal, 25 (57%) hypopharyngeal, and 23 (55%) uterine cervical cancer samples. PAR1 was expressed in 45 (57%) oropharyngeal, 22 (50%) hypopharyngeal, and 22 (50%) uterine cervical cancer samples. Patients diagnosed with p16-positive oropharyngeal cancer had a substantially improved prognosis compared to those diagnosed with p16-negative cancer. The PAR1-negative cases had a considerably improved prognosis compared to the positive cases (disease-specific survival [DSS] and -negative cases (disease-free survival [DFS]). Multivariate analysis revealed that ARRDC3-positive cases had an appreciably better DSS prognosis than patients with p16-negative oropharyngeal cancers. PAR1-positive patients among patients with p16-positive oropharyngeal cancer had a poor prognosis. With respect to DFS, patients with PAR1-positive and p16-negative oropharyngeal cancer had a 35-fold higher recurrence rate than those with PAR1-negative and p16-negative oropharyngeal cancer. Our results suggest that PAR1 expression affects the prognosis and recurrence rate of HPV-associated oropharyngeal cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Human papillomavirus (HPV)-associated oropharyngeal cancer occasionally has a poor prognosis, making prognostic risk stratification crucial. Protease-activated receptor-1 (PAR1) is involved in carcinogenesis, and its expression is regulated by alpha-arrestin domain-containing protein 3 (ARRDC3). It is also involved in the tumor microenvironment. We sought to evaluate the predictive ability of PAR1, ARRDC3, and tumor-infiltrating lymphocyte (TIL) scores in patients with oropharyngeal, hypopharyngeal, and uterine cervical cancers, serving as comparators for HPV-associated oropharyngeal cancer.
METHODS
METHODS
Immunohistochemical analysis of p16, ARRDC3, and PAR1 expression was performed on 79 oropharyngeal, 44 hypopharyngeal, and 42 uterine cervical cancer samples. The TIL scores were assessed and classified into the following groups based on invasion: low: 0-10%, medium: 20-40%, and high: > 50%. For prognostic analysis, the three groups were evaluated by dividing them into low, medium, and high categories, or alternatively into two groups using the median value as the cutoff.
RESULTS
RESULTS
p16 was expressed in 44 (56%) oropharyngeal, 8 (18%) hypopharyngeal, and all uterine cervical cancer samples. ARRDC3 was detected in 39 (49%) oropharyngeal, 25 (57%) hypopharyngeal, and 23 (55%) uterine cervical cancer samples. PAR1 was expressed in 45 (57%) oropharyngeal, 22 (50%) hypopharyngeal, and 22 (50%) uterine cervical cancer samples. Patients diagnosed with p16-positive oropharyngeal cancer had a substantially improved prognosis compared to those diagnosed with p16-negative cancer. The PAR1-negative cases had a considerably improved prognosis compared to the positive cases (disease-specific survival [DSS] and -negative cases (disease-free survival [DFS]). Multivariate analysis revealed that ARRDC3-positive cases had an appreciably better DSS prognosis than patients with p16-negative oropharyngeal cancers. PAR1-positive patients among patients with p16-positive oropharyngeal cancer had a poor prognosis. With respect to DFS, patients with PAR1-positive and p16-negative oropharyngeal cancer had a 35-fold higher recurrence rate than those with PAR1-negative and p16-negative oropharyngeal cancer.
CONCLUSION
CONCLUSIONS
Our results suggest that PAR1 expression affects the prognosis and recurrence rate of HPV-associated oropharyngeal cancer.
Identifiants
pubmed: 37486532
doi: 10.1007/s12105-023-01567-5
pii: 10.1007/s12105-023-01567-5
pmc: PMC10514014
doi:
Substances chimiques
Biomarkers, Tumor
0
Cyclin-Dependent Kinase Inhibitor p16
0
Receptor, PAR-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
658-672Subventions
Organisme : Research Project Grants from Kawasaki Medical University
ID : R04G-001
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
FEBS Lett. 2018 Feb;592(4):599-609
pubmed: 29364502
Lancet Oncol. 2016 Apr;17(4):440-451
pubmed: 26936027
PLoS One. 2012;7(6):e38711
pubmed: 22701698
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2185-2191
pubmed: 32333138
Viruses. 2021 Sep 08;13(9):
pubmed: 34578368
Lancet Oncol. 2014 Feb;15(2):e58-68
pubmed: 24480556
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
New Microbiol. 2013 Apr;36(2):133-44
pubmed: 23686119
Head Neck. 2012 Apr;34(4):459-61
pubmed: 22180304
Int J Cancer. 2016 Jan 1;138(1):171-81
pubmed: 26178914
Curr Mol Med. 2017;17(3):221-229
pubmed: 28782483
Oncoimmunology. 2015 Jan 30;4(1):e965570
pubmed: 25949860
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
Int J Gen Med. 2021 Mar 22;14:967-981
pubmed: 33790626
N Engl J Med. 2007 May 10;356(19):1944-56
pubmed: 17494927
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Br J Cancer. 2014 Jan 21;110(2):489-500
pubmed: 24169344
Hum Mol Genet. 2019 Jan 15;28(2):341-348
pubmed: 30412241
J Clin Oncol. 2013 Mar 1;31(7):845-52
pubmed: 23182993
Mol Cancer Res. 2004 Jul;2(7):395-402
pubmed: 15280447
Int J Mol Sci. 2018 Jun 27;19(7):
pubmed: 29954076
J Thromb Haemost. 2021 Jan;19(1):161-172
pubmed: 33064371
Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1660-1667
pubmed: 31358520
Mod Pathol. 2016 Oct;29(10):1155-64
pubmed: 27363491
Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):553-61
pubmed: 19427557
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Cancer Res. 2007 Jan 1;67(1):354-61
pubmed: 17210718
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Biol Chem. 2018 Mar 2;293(9):3350-3362
pubmed: 29348172
Bioengineered. 2021 Dec;12(1):5334-5347
pubmed: 34415232
J Clin Oncol. 2004 Jan 1;22(1):69-76
pubmed: 14657228
Oncology. 2014;87(3):173-82
pubmed: 25033838
Head Neck Pathol. 2017 Sep;11(3):354-363
pubmed: 28032290
J Clin Oncol. 2003 Jan 1;21(1):92-8
pubmed: 12506176
J Clin Oncol. 2008 Jul 20;26(21):3582-9
pubmed: 18559875
Cancer Manag Res. 2020 Dec 23;12:13233-13239
pubmed: 33380831
Am J Cancer Res. 2018 Jan 01;8(1):132-143
pubmed: 29416926
Nat Struct Mol Biol. 2018 Jan;25(1):4-12
pubmed: 29323277
Histopathology. 2019 Jul;75(1):146-150
pubmed: 31144335
J Clin Oncol. 2015 Mar 20;33(9):983-91
pubmed: 25534375
Lancet. 2019 Jan 5;393(10166):51-60
pubmed: 30449623
Oncogene. 2010 Feb 25;29(8):1093-102
pubmed: 19946335
Cancer. 2016 Jul 1;122(13):2021-30
pubmed: 27111669
JAMA Oncol. 2022 Jun 1;8(6):1-7
pubmed: 35482348
Oncogene. 2010 Sep 9;29(36):5032-47
pubmed: 20603614
Br J Cancer. 1999 Feb;79(5-6):707-17
pubmed: 10070858
Sci Rep. 2014 Jan 24;4:3846
pubmed: 24457910